Our pipeline of high-value
product opportunities
product opportunities
T-cell immunosuppressive portfolio
Our strategy is to develop
distinct small molecule t-cell
immunosuppressives for
multiple indications.
LIFE-001 (Calcineurin inhibitor (CNi))
for Organ Transplantation
More than 400,000 patients are living with solid organ transplants in the U.S. alone.
LifeMine is developing a long-acting CNi injectable, LIFE-001, for solid organ transplantation that has the potential to improve both safety and reduce organ rejection associated with current standards of care (SOC) such as tacrolimus. Patients on current SOC struggle with toxicity and medication adherence, adversely affecting outcomes.
We believe LIFE-001 will address an important unmet clinical need with the potential to improve safety, reduce organ rejection and save the lives of patients.
Anti-fungal portfolio
Fungal infections represent
a large and growing global
medical issue with
1.7 million deaths annually
across the globe.
Emerging new therapies (e.g., hematopoietic stem cell transplantation, CAR-T and other immunosuppressive therapies), have an unacceptably high incidence of life-threatening fungal infections.
Key areas of unmet need include acute invasive candida and aspergillus infection, allergic bronchopulmonary aspergillosis and endemic fungal infections. The drug of last resort for life-threatening fungal infections, amphotericin, has such high toxicity that it is widely derided as “amphoterrible.”
LifeMine is uniquely positioned to discover the best antifungal molecules that can address the limitations of current medicines and serve as transformational medicines for millions of patients.
Drug Discovery & Development Alliance with
LifeMine and GlaxoSmithKline (GSK) entered a drug discovery and development alliance, the first such agreement in genomic drug discovery from fungi, to identify novel small molecule leads directed to up to three human targets provided by GSK addressing multiple disease areas.